Search Within

David J Straus

Formats
  1. Meeting Abstract (168)
  2. Journal Article (166)
  3. Book Section (15)
  4. Conference Paper (5)
  5. Research Letter (3)
  6. Editorial (2)
  7. Correspondence (1)
  8. Review (1)
Groups
  1. Center for Hematologic Malignancies (361)
  2. Department of Medicine (361)
  3. Hematologic Malignancies, Division of (361)
  4. Lymphoma (361)
  5. Survivorship Research (162)
  6. Population Sciences Research Program (129)

More Groups

People
  1. Andrew Zelenetz (163)
  2. Ariela Noy (139)
  3. Paul Hamlin (122)
  4. Steven Horwitz (122)
  5. Craig Moskowitz (117)
  6. Matthew Matasar (104)

More People

Years
  1. 2024 (10)
  2. 2023 (9)
  3. 2022 (13)
  4. 2021 (27)
  5. 2020 (25)
  6. 2019 (21)

More Years

Publications
  1. Blood (117)
  2. Journal of Clinical Oncology (44)
  3. Hematological Oncology (19)
  4. Cancer (14)
  5. Leukemia and Lymphoma (13)
  6. British Journal of Haematology (11)

More Publications

Publishers
  1. American Society of Hematology (124)
  2. American Society of Clinical Oncology (46)
  3. Wiley Blackwell (36)
  4. Elsevier Inc. (23)
  5. Taylor & Francis Group (14)
  6. John Wiley & Sons (12)

More Publishers

Results (361)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • IVAC with or without rituximab for relapsed or refractory B-cell non-Hodgkin lymphomas: Real-world experience in the modern era
    Journal Article

    Buege, M. J.; Dao, P. H.; Drill, E.; LeVoir, A.; Pak, T.; Peterson, T. J.; Straus, D. J.
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study
    Meeting Abstract

    Crosswell, H. E.; LaCasce, A. S.; Bartlett, N. L.; Straus, D. J.; Savage, K. J.; Zinzani, P. L.; Collins, G. P.; Fanale, M. A.; Fenton, K.; Dong, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Khimani, F.; Shustov, A. R.; Shadman, M.; Ruan, J.; Moskowitz, A. J.; Straus, D. J.; Kumar, A.; Sauter, C. S.; Zelenetz, A. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Progress in understanding the biology of nodular lymphocyte-predominant Hodgkin lymphoma
    Editorial

    Straus, D. J.
    Haematologica (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin with chemotherapy for patients with previously untreated stage III/IV classical Hodgkin lymphoma: 5-year update of the ECHELON-1 study
    Meeting Abstract

    Ramchandren, R.; Długosz-Danecka, M.; Connors, J. M.; Radford, J.; Illés, A.; Picardi, M.; Lech-Maranda, E.; Feldman, T.; Smolewski, P.; Savage, K. J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts
    Journal Article

    Mehta-Shah, N.; Lunning, M. A.; Moskowitz, A. J.; Boruchov, A. M.; Ruan, J.; Lynch, P.; Hamlin, P. A.; Leonard, J.; Matasar, M. J.; Myskowski, P. L.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S. V.; Drill, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Batlevi, C.; Drullinsky, P.; Grieve, C.; Laraque, L.; Joseph, A.; Mahajan, N.; Matasar, M.; Straus, D.; Zelenetz, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save